Skip to main content
Clinical Trials/JPRN-jRCT2080220477
JPRN-jRCT2080220477
Unknown
Phase 3

A study to evaluate the effects of human lymphoblastoid interferon (HLBI) in hepatitis C patients with compensated cirrhosis.

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Chronic hepatitis C with compensated cirrhosis
Sponsor
Dainippon Sumitomo Pharma Co., Ltd.
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 5, 2007
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • \-Compensated cirrhosis patients
  • \-Patients aged 20 to less than 76
  • \-Patients with chronic liver diseases except chronic hepatitis C with compensated cirrhosis, such as autoimmune hepatitis, alcoholic hepatitis, and drug\-induced liver injury.
  • \-Decompensated cirrhosis patients

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials